Looking Into C4 Therapeutics's Return On Capital Employed
Portfolio Pulse from Benzinga Insights
C4 Therapeutics (NASDAQ:CCCC) reported Q1 sales of $3.76 million and a loss of $34.78 million. The company posted a negative Return on Capital Employed (ROCE) of -0.13%, suggesting inefficient capital allocation. However, Q1 earnings per share of $-0.71 beat analyst predictions of $-0.75.
May 18, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
C4 Therapeutics reported Q1 sales of $3.76 million and a loss of $34.78 million. The company posted a negative ROCE of -0.13%, suggesting inefficient capital allocation. However, Q1 earnings per share of $-0.71 beat analyst predictions of $-0.75.
C4 Therapeutics' negative ROCE of -0.13% indicates inefficient capital allocation, which could negatively impact the stock price. However, the company's Q1 earnings per share beat analyst predictions, which may offset the negative impact of the ROCE. As a result, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100